Sino Biopharmaceutical Limited Stock Performance
| SBMFF Stock | USD 0.45 0.03 7.14% |
Sino Biopharmaceutica has a performance score of 6 on a scale of 0 to 100. The entity has a beta of 0.15, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Sino Biopharmaceutica's returns are expected to increase less than the market. However, during the bear market, the loss of holding Sino Biopharmaceutica is expected to be smaller as well. Sino Biopharmaceutical right now has a risk of 2.35%. Please validate Sino Biopharmaceutica kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if Sino Biopharmaceutica will be following its existing price patterns.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Sino Biopharmaceutical Limited are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite nearly unfluctuating technical and fundamental indicators, Sino Biopharmaceutica may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
| Begin Period Cash Flow | 10.6 B | |
| Total Cashflows From Investing Activities | -2.5 B | |
| Free Cash Flow | 3.5 B |
Sino |
Sino Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest 41.00 in Sino Biopharmaceutical Limited on December 28, 2024 and sell it today you would earn a total of 4.00 from holding Sino Biopharmaceutical Limited or generate 9.76% return on investment over 90 days. Sino Biopharmaceutical Limited is currently producing 0.1817% returns and takes up 2.3536% volatility of returns over 90 trading days. Put another way, 21% of traded pink sheets are less volatile than Sino, and 97% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Sino Biopharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sino Biopharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Sino Biopharmaceutical Limited, and traders can use it to determine the average amount a Sino Biopharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0772
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SBMFF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.35 actual daily | 20 80% of assets are more volatile |
Expected Return
| 0.18 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Sino Biopharmaceutica is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sino Biopharmaceutica by adding it to a well-diversified portfolio.
Sino Biopharmaceutica Fundamentals Growth
Sino Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Sino Biopharmaceutica, and Sino Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sino Pink Sheet performance.
| Return On Equity | 0.29 | |||
| Return On Asset | 0.0451 | |||
| Profit Margin | 0.29 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 10.34 B | |||
| Shares Outstanding | 18.81 B | |||
| Price To Earning | 24.17 X | |||
| Price To Book | 2.51 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 26.86 B | |||
| EBITDA | 19.87 B | |||
| Cash And Equivalents | 15.67 B | |||
| Cash Per Share | 0.85 X | |||
| Total Debt | 5.21 B | |||
| Debt To Equity | 0.31 % | |||
| Book Value Per Share | 1.64 X | |||
| Cash Flow From Operations | 5.37 B | |||
| Earnings Per Share | 0.06 X | |||
| Total Asset | 60.54 B | |||
| Current Asset | 13.73 B | |||
| Current Liabilities | 7.73 B | |||
About Sino Biopharmaceutica Performance
By analyzing Sino Biopharmaceutica's fundamental ratios, stakeholders can gain valuable insights into Sino Biopharmaceutica's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Sino Biopharmaceutica has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sino Biopharmaceutica has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the Peoples Republic of China. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong. Sino Biopharmaceutic is traded on OTC Exchange in the United States.Things to note about Sino Biopharmaceutical performance evaluation
Checking the ongoing alerts about Sino Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Sino Biopharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sino Biopharmaceutica has some characteristics of a very speculative penny stock | |
| About 48.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Sino Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sino Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining Sino Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sino Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sino Biopharmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sino Biopharmaceutica's pink sheet. These opinions can provide insight into Sino Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Sino Pink Sheet analysis
When running Sino Biopharmaceutica's price analysis, check to measure Sino Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sino Biopharmaceutica is operating at the current time. Most of Sino Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sino Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sino Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sino Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |